Team identifies, advances a drug that targets metabolic vulnerability and impairs cancer cell growth and survival
A drug discovered and advanced by The University of Texas MD Anderson Cancer Center's Institute for Applied Cancer Science (IACS) and the Center for Co-Clinical Trials (CCCT) inhibits a vital metabolic process required for ...
Jun 11, 2018
0
54